FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:2222-2225 November 29, 2007 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Audio Interview Slide Presentation Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Dengue is an important human viral disease transmitted by insects. Although nearly half the world's population is at risk for infection and as many as 100 million cases occur annually,¹ we have no antiviral drugs to treat it and no vaccines to prevent it. A closely related but much more lethal mosquito-borne virus, yellow fever, used to be one of the great scourges among humans. Although yellow fever is now largely controlled by vaccination, many regions are susceptible to a reemergence if the disease is introduced by travelers, and substantial recent problems with vaccine safety will no doubt change vaccination . . . [Full Text of this Article]

Source Information

Dr. Monath is a partner at the venture-capital firm Kleiner Perkins Caulfield & Byers, Menlo Park, CA, and an adjunct professor at the Harvard School of Public Health, Boston.

An interview with Dr. Monath and a slide show are available at www.nejm.org.

This article has been cited by other articles:

• Wright, P. F., Durbin, A. P., Whitehead, S. S., Ikizler, M. R., Henderson, S., Blaney, J. E., Thumar, B., Ankrah, S., Rock, M. T., McKinney, B. A., Murphy, B. R., Schmidt, A. C. (2009). Phase 1 Trial of the Dengue Virus Type 4 Vaccine Candidate rDEN4{Delta}30-4995 in Healthy Adult Volunteers. Am J Trop Med Hyg 81: 834-841 [Abstract] [Full Text]